The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1275 articles
Jelly Roll's wife, Bunnie Xo, described a 'horrific' bout of suicidal ideation as a side effect from taking a GLP-1 medication last year. The Dumb Blonde podcast host opened up to PEOPLE about this dark period, emphasizing the need for open conversations on GLP-1 side effects. Despite family diabetes history prompting her use, she urges others: 'Please stay.'
The surge in GLP-1 drug use, with 12% of U.S. adults already on them, is costing more than just patients—their high prices are fueling 30% of recent health insurance premium hikes, says Harvard's Luca Maini. While effective for weight loss, these blockbuster meds face patent protections and coverage hurdles. Discover the full economic ripple effects and what's ahead.
Eli Lilly is stockpiling $1.5 billion worth of its oral obesity drug orforglipron to avoid the supply shortages that hampered early GLP-1 launches. With an expected FDA decision on April 10, the company aims for a swift global rollout against Novo Nordisk's Wegovy pill. This strategic move signals big changes in accessible weight loss therapy.
Popular GLP-1 drugs like Ozempic and Wegovy are curbing appetites, prompting restaurants to adapt with specialized menus. Cuba Libre's Barry Gutin explains their high-protein, smaller-portion offerings designed with a doctor's input. This trend signals a lasting change in dining habits.
GLP-1 medications like Ozempic and Wegovy have surged in popularity for weight loss and Type II diabetes management, but celebrities are now sharing alarming side effects. Bunnie Xo revealed suicidal ideations after using one, while her husband Jelly Roll shed nearly 300 pounds naturally. This guide examines the risks and promotes healthier paths.
Telehealth giant Hims & Hers stirred controversy by launching a cheap compounded version of Novo Nordisk's Wegovy pill, only to yank it days later amid FDA crackdowns and lawsuits. This incident highlights the ongoing Wild West in the knockoff GLP-1 market, where unapproved compounded drugs flood the scene despite resolved shortages. Patients risk ineffective or unsafe products—here's what you need to know.
Novo Nordisk's lawsuit against Hims & Hers claims compounded semaglutide sales are illegal now that shortages ended. But is this about patient safety or enforcing high prices like $150/month for Wegovy pills versus $50 alternatives? Dive into how patents create artificial semaglutide shortages.
McDonald's executives revealed plans to cater to the growing number of customers on GLP-1 drugs like Ozempic during their latest earnings call. With users seeking high-protein options and avoiding sugary drinks, the chain is testing menu tweaks. This shift reflects broader changes in the food industry as GLP-1 adoption hits 10% of the US population.
A nasal spray version of semaglutide, the active ingredient in Ozempic and Wegovy, could soon offer an affordable alternative for weight loss. Chinese firm Shanghai Shiling Pharmaceutical is advancing trials, aiming for global markets by 2028 amid soaring demand. This development aligns with Novo Nordisk's upcoming patent loss in China, paving the way for cheaper generics.
